BUSINESS DEVELOPMENT


HOME > BUSINESS DEVELOPMENT > Investor Relations
BUSINESS DEVELOPMENT
Investor Relations


Financingcalendar:

Round A:At the beginning of 2016, we received on the A round of 20 million yuan from Shenogen Pharma Group (hereinafter referred to as "Shenogen"), all of the amount of financing is going to be used for research and development.

Shenogen is based on research and development of new drugs as the leading high-tech enterprises, with the only new female Hormone receptor ER-alpha 36 drug target global patent,committing to the development of the world's first targeting and immunotherapy of anti-cancer drugs, has developed a series of small molecules and antibody drugs indicating liver cancer, breast cancer leukemia, and other tumors .

Round B:In May 2017, we re-launched the financing to complete clinical trials of the M802 (HER2 / CD3), M701 (EpCAM /CD3) project, and quickly promote research and development progress of the following-up pipeline, as well as looking for global strategic partners. we welcome purposeful investment institutions, pharmaceutical companies to discuss the cooperations.